Table 6 Demographical, oncological, and echocardiographic data of patients who had an abnormally elevated level of plasma NT-pro BNP in the follow-up visit

Age (years)

53

65

47

60

58

Site of cancer

R

L

L

R

R

FH of cancer

YES

NO

NO

NO

NO

Type of cancer

IDC II

IDC II

IDC II

IDC II

IDC II

TNM staging

2,1,0

2,1,0

2,0,0

2,1,0

2,1,0

Progesterone receptors

Positive

Positive

Positive

Negative

Negative

Estrogen receptors

Negative

Negative

Positive

Negative

Negative

HER2

Positive

Positive

Positive

Positive

Positive

Chemotherapy type 1

A

E

E

A

E

Dose in mg/cycle

110

100

160

90

150

Cumulative dose in mg (after 3 cycles)

330

300

480

270

450

Chemotherapy type 2

C

C

C

C

C

Dose in mg per cycle

1100

1000

1200

900

1000

Cumulative dose in mg (after 3 cycles)

3300

3000

3600

2700

3000

Timing of surgery

Before chemotherapy

Before chemotherapy

Before chemotherapy

Before chemotherapy

Before chemotherapy

2D LVEF (baseline)

57

64

60

60

59

2D LVEF (FU)

64

54

59

58

55

Relative change of 2D LVEF^a

+ 0.12

− 0.16

− 0.02

− 0.03

− 0.07

2D-GLS (Baseline)

− 21

− 20

− 22

− 16

− 27

2D-GLS (FU)

− 17

− 15

− 18

− 14

-18

Relative change of 2D-GLS^a

− 0.19

− 0.25

− 0.18

− 0.13

− 0.33

3D LVEF (Baseline)

55.8

57.7

60.2

60.7

69.0

3D LVEF (FU)

56.0

57.0

60.0

62.0

59.0

Relative change of 3D-LVEF^a

+0.004

− 0.012

− 0.003

+0.021

− 0.145

NT-pro BNP, pg/ml (Baseline)

36.5

66

81.5

459

34.3

NT-pro BNP, pg/ml (FU)

342

459

324.6

977.5

208

Relative change of NT-proBNP

+8.4

+6.0

+3.0

+1.1

+5.1